IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury

Journal of Clinical Investigation

Volumn 106, Issue 6, 2000, Pages 783-791

  Corne, Jonathan ^a,b   Chupp, Geoffrey ^a   Lee, Chun Guen ^a   Homer, Robert J ^a   Zhu, Zhou ^a   Chen, Qingsheng ^a   Ma, Bing ^a   Du, Yuefen ^a   Roux, Francoise ^a   McArdle, John ^a   Waxman, Aaron B ^a,c   Elias, Jack A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 3; VASCULOTROPIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPEROXIA; LUNG DISEASE; LUNG INJURY; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TRANSGENIC MOUSE;

EID: 0033796032     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9674     Document Type: Article

References (47)

1. Crapo, J.D. 1986. Morphologic changes in pulmonary oxygen toxicity. Annu. Rev. Physiol. 48:721-731.
2. Crapo, J.D., Barry, B.E., Foscue, H.A., and Shelburne, J. 1980. Structural and biochemical changes in rat lungs occurring during exposure to lethal and adaptive doses of oxygen. Am. Rev. Respir. Dis. 122:123-143.
3. Waxman, A.B., et al. 1998. Targeted lung expression of interleukin-11 enhances marine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin. Invest. 101:1970-1982.
4. de Vries, J.E. 1998. The role of IL-13 and its receptor in allergy and inflammatory responses. J. Allergy Clin. Immunol. 102:165-169.
5. Minty, A., et al. 1997. The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. Eur. Cytokine Netw. 8:203-213.
6. Emson, C.L., Bell, S., Jones, A., Wisden, W., and McKenzie, A.N.J. 1998. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J. Exp. Med 188:399-404.
7. Zurawski, G., and de Vries, J.E. 1994. Interleukin-13, an interleukin-4-like cycokine that acts on monocytes and B cells, but not on T cells. lmmunol. Today. 15:19-26.
8. Bochner, B.S., Klunk, D.A., Sterbinsky, S.A., Coffman, R.L., and Schleimer, R.P. 1995. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J. Immunol. 154:799-803.
9. Lentsch, A.B., Shanley, T.P., Sarma, V., and Ward, P.A. 1997. In vivo suppression of NF-κB and preservation of IkBα by interleukin-10 and interleukin-13. J. Clin. Invest. 100:2443-2448.
10. Lentsch, A.B., Czermak, B.J., Jordan, P.A., and Ward, P.A. 1999. Regulation of acute lung inflammatory injury by endogenous IL-13. J. Immunol. 162:1071-1076.
11. Watson, M.L., et al. 1999. Anti-inflaminatory actions of interleukin-13: Suppression of tumor necrosis factor-α and antigen-induced leukocyte accumulation in the guinea pig lung. Am. J. Respir. Cell Mol. Biol. 20:1007-1012.
12. Manna, S.K., and Aggarwal, B.B. 1998. IL-13 suppresses TNF-induced activation of NF-κB, activation protein-1, and apoptosis. J. Immunol. 161:2863-2872.
13. Vannier, E., de Waal, M.R., Salazar-Montes, A., de Vries, J.E., and Dinarello, C.A. 1996. Interleukin-13 (IL-13) induces receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein. Blood. 87:3307-3315
14. Yoshidome, H., Kato, A., Miyazaki, M., Edwards, M.J., and Lentsch, A.B. 1999. IL-13 activates STAT6 and inhibits liver injury induced by ischemia/reperfusion. Am. J. Pathol. 155:1059-1064.
15. Muchamuel, T., Menon, S., Pisacane, P., Howard, M.C., and Cockayne, D.A. 1997. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-α, IFN-γ, and IL-12 production. J. Immunol. 158:2898-2903.
16. Marie, O., Thillaye-Goldenberg, B., Naud, M.D., and de Kozak, V. 1999. Inhibition of endotoxin-induced uveitis and potentiation of local TNF-α and interleukin-6 mRNA expression by interleukin-13. Invest. Ophthalmol. Vis. Sci. 40:2275-2282.
17. Maniscalco, W.M., Watkins, R.H., Finkelstein, J.N., and Campbell, M.H. 1995. Vascular endothelial growth factor mRNA increases in alveolar epithelial cells during recovery from oxygen injury. Am. J. Respir. Cell Mol. Biol. 13:377-386.
18. Watkins, R.H., D'Angio, C.T., Ryan, R.M., Patel, A., and Maniscalco, W.M. 1999. Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. Am. J. Physiol. 276:L858-L867.
19. Deneke, S.M., and Fanburg, B.L. 1982. Oxygen toxicity of the lung: an update. Br. J. Anaesth. 54:737-749.
20. Adamson, I.Y.R., Bowden, D.H., and Wyatt, J.P. 1970. Oxygen poisoning in mice. Ultrastructural and surfactant studies during exposure and recovery. Arch. Pathol. 90:463-472,
21. Smith, L.J. 1985. Hyperoxic lung injury: biochemical, cellular, and morphologic characterization in the mouse. J. Lab. Clin. Med. 106:269-278.
22. Durr, R.A., Dubaybo, B.A., and Thet, L.A. 1987. Repair of chronic hyperoxic lung injury: changes in lung ultrastructure and matrix. Exp. Mol. Pathol 47:219-240.
23. Ferrara, N., and Davis-Smyth,T. 1997. The biology of vascular endothelial growth factor. Endocr. Rev. 18:4-25.
24. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:9-22.
25. Alon, T., et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1:1024-1028.
26. Gerber, H.-P., et al. 1999. VEGF is required for growth and survival in neonatal mice. Development. 126:1149-1159.
27. Girard, N., Maingonnat, C., Bertrand, P., Vasse, M., and Delpech, B. 1999. Hyaluronectin secretion by monocytes; downregulation by IL-4 and IL-13, upregulation by IL-10. Cytokine. 11:579-584.
28. Volpert, O.V., et al. 1998. Inhibition ofangiogenesis by interleukin-4. J. Exp. Med. 188:1039-1046.
29. Halloran, M.M., Haskell, C.J., Woods, J.M., Hosaka, S., and Koch, A.E. 1997. Interleukin-13 is an endothelial chemotaxin. Pathobiology. 65:287-292.
30. Zhu, Z., et al. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities and eotaxin production. J. Clin. Invest. 103:779-788.
31. Ray, P., et al. 1997. Regulated overexpression of interleukin-11 in the lung: use to dissociate development-dependent and -independent phenotypes. J. Clin. Invest. 100:2501-2511.
32. Panos, R.J., Bak, P.M., Simonet, W.S., Rubin, J.S., and Smith, L.J. 1995. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J. Clin. Invest. 96:2026-2033.
33. Tischer, E., et al. 1991. The human gene for vascular endothelial growth factor. J Biol. Chem. 266:11947-11954.
34. Barazzone, C., Horowitz, S., Donati, V.R., Rodriguez, I., and Piguet, P.-F. 1998. Oxygen toxicity in mouse lung: pathways to cell death. Am. J. Respir. Cell Mol Biol. 19:573-581.
35. Fehrenbach, H., Kasper, M., Haase, M., Schuh, D., and Muller, M. 1999. Differential immunolocalization of VEGF in the rat and human adult lung, and in experimental rat lung fibrosis: light, fluorescence, and electron microscopy. Anat. Rec. 254:61-73.
36. Berse, B., Brown, L.F., Van de Water, L., Dvorak, H.H., and Senger, D.R. 1992. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol. Biol. Cell. 3:211-220.
37. Chiramonte, M.G., Donaldson, D.D., Cheever, A.W., and Wynn, T.A. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 104:777-785.
38. Wills-Karp, M., et al. 1998 Interleukin-13: central mediator of allergic asthma. Science. 282:2258-2260.
39. Kikuchi, K., et al. 1998. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br. J. Dermatol. 139:1049-1051.
40. Matsumoto, K., Ohi, H., and Kanmatsuse, K. 1997. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron. 77:212-218.
41. Bradding, P., Redington, A.E., and Holgate, S.T. 1997. Airway wall remodelling in the pathogenesis of asthma: cycokine expression in the airways. In Airway wall remodelling in asthma. A.G. Stewart, editor. CRC Press Inc. Boca Raton, Florida, USA. 29-63.
42. Chiaramonte, M.G., et al. 1999. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J. Immunol. 162:920-930.
43. Keyt, B.A., et al. 1996 The carboxy/-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitrogemc potency. J. mol. Chem. 271:7788-7795.
44. Plouet, J., et al. 1997. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form of urokinase is required for its mirogenic effect. J. Biol. Chem 272:13390-13396.
45. Roberts, W.G., and Palade, G.E. 1997. Neovasculature induced by vascular endothelial growth factor is fenestraced. Cancer Res. 57:765-772.
46. Sozzani, P., et al. 1998. IL-13 induces tyrosine phosphorylation of phospholipase C gamma-1 following IRS-2 association in human monocytes: relationship with the inhibitory effect of IL-13 on ROI production. Biochem. Biophys. Res. Commun. 244:665-670.
47. Tokieda, K., et al. 1999. Surfactant protein-B-deflcient mice are susceptible to hypetoxic lung injury. Am. J. Respir. Cell Mol. Biol. 21:463-472.